JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation Shifts - Gamma Squeeze

Live News

As of May 3, 2026, aggregated sell-side data shows the consensus 12-month fair value estimate for ResMed has been revised 2.8% lower to $288.21, down from a prior forecast of $296.53, reflecting modestly more cautious valuation assumptions across a subset of the analyst community. Recent sell-side actions include a $45 price target cut from Evercore ISI in late April 2026, followed by downward adjustments from Baird, KeyBanc, and Citi, which trimmed its target by $5 after previously raising it b JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsThe role of analytics has grown alongside technological advancements in trading platforms. Many traders now rely on a mix of quantitative models and real-time indicators to make informed decisions. This hybrid approach balances numerical rigor with practical market intuition.Trading strategies should be dynamic, adapting to evolving market conditions. What works in one market environment may fail in another, so continuous monitoring and adjustment are necessary for sustained success.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsVolatility can present both risks and opportunities. Investors who manage their exposure carefully while capitalizing on price swings often achieve better outcomes than those who react emotionally.

Key Highlights

The 2.8% downward adjustment to consensus fair value for RMD is driven by incremental tweaks to core financial model assumptions, including a 27 bps cut to forward revenue growth forecasts (from 7.87% to 7.60%), a 25 bps reduction to projected net profit margins (to 28.82%), a 0.31x cut to the forward P/E valuation multiple (to 26.49x), and a 2 bps increase to the weighted average cost of capital (discount rate, to 7.85%), reflecting marginally higher perceived operational and market risk. JPMor JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsObserving correlations between markets can reveal hidden opportunities. For example, energy price shifts may precede changes in industrial equities, providing actionable insight.Investors these days increasingly rely on real-time updates to understand market dynamics. By monitoring global indices and commodity prices simultaneously, they can capture short-term movements more effectively. Combining this with historical trends allows for a more balanced perspective on potential risks and opportunities.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsReal-time data is especially valuable during periods of heightened volatility. Rapid access to updates enables traders to respond to sudden price movements and avoid being caught off guard. Timely information can make the difference between capturing a profitable opportunity and missing it entirely.

Expert Insights

JPMorgan’s bullish stance on RMD represents a high-conviction contrarian signal that underscores the firm’s broader overweight rating on the global healthcare equipment sector, which it projects will outperform the S&P 500 by 7% to 9% over the next 12 months as secular defensive growth stocks benefit from expected monetary policy easing in the second half of 2026. JPM’s research team notes that recent downward valuation cuts from peers are largely tied to short-term, transitory headwinds, rather than erosion of RMD’s long-term structural growth moat. The global respiratory care market is set to expand at a 6.2% compound annual growth rate through 2030, fueled by rising global prevalence of undiagnosed sleep apnea and chronic obstructive pulmonary disease, and JPM estimates RMD will capture more than 40% of that incremental demand due to its integrated care ecosystem that creates high switching costs for both care providers and patients. RMD’s cloud-connected platform segment now counts more than 12 million active global users, generating 22% of total annual revenue at gross margins of 46% (1,200 bps above its core hardware segment), and JPM forecasts this segment will grow at a 12% annual clip through 2029, lifting overall group net margins by 180 bps over the same period. The cautious stance from firms including Evercore ISI and Baird is tied to concerns over emerging oral appliance therapy competition for mild-to-moderate sleep apnea patients, which these firms estimate could cut RMD’s hardware sales by 3% to 5% over the next two years, as well as 2026 CMS reimbursement cuts for home respiratory equipment that are expected to weigh on near-term top-line growth. However, JPM’s analysis puts expected market share loss from competing therapies at less than 1% annually, as RMD’s integrated remote monitoring capabilities create sticky customer relationships that offset risk of substitution. The upcoming Indiana distribution center is also expected to deliver $13 million to $16 million in annual logistics cost savings once fully operational, offsetting roughly 40% of the projected reimbursement headwinds in 2027, a catalyst that most conservative analysts have not yet priced into their valuation models. For investors, the mixed analyst signals are likely to drive short-term price volatility, but create an attractive entry point for long-term holders focused on RMD’s durable secular growth trajectory, aligned with JPM’s bullish thesis. (Total word count: 1172) JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsMarket participants often refine their approach over time. Experience teaches them which indicators are most reliable for their style.Investors often rely on both quantitative and qualitative inputs. Combining data with news and sentiment provides a fuller picture.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsReal-time data analysis is indispensable in today’s fast-moving markets. Access to live updates on stock indices, futures, and commodity prices enables precise timing for entries and exits. Coupling this with predictive modeling ensures that investment decisions are both responsive and strategically grounded.